FORMA Therapeutics announced an exclusive alliance with Janssen Biotech in which the two companies will collaborate on the discovery, development and commercialization of novel small molecule drug candidates that target tumor metabolism mechanisms. Read the full story
Tag Archive | "co-development"
AstraZeneca and Hutchison MediPharma enter into global licensing, co-development, and commercialisation agreement for Volitinib
Posted on 21 December 2011
AstraZeneca and Hutchison MediPharma have entered into a global licensing, co-development, and commercialisation agreement for Volitinib (HMPL-504), a novel targeted therapy and a highly selective inhibitor of the c-Met receptor tyrosine kinase for the treatment of cancer. Read the full story
AgonOx partners with MedImmune for development of OX40 agonists in cancer therapy
Posted on 01 November 2011
Exclusive global partnership with MedImmune to develop agonists using its OX40 platform. Read the full story
Merck KGaA / Ono: Co-development and co-marketing agreement for Stimuvax
Posted on 05 October 2011
Merck and Ono Pharmaceutical form collaborations to develop oral Multiple Sclerosis drug and cancer immunotherapy. Read the full story
Co-development, licensing and co-promotion agreement for Orencia
Posted on 21 September 2011
Bristol-Myers Squibb and Ono Pharmaceutical will co-develop and co-commercialize ORENCIA, a biologic therapy for rheumatoid arthritis, in Japan. Read the full story
